Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy

Abstract

Reduced innate immunity in non-responders may explain reduced efficacy to anti-TNF therapy. These serological markers may prove useful in predicting the outcome of costly anti-TNF therapy.